Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Immune-related Adverse Events × tocilizumab × Other solid neoplasm × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 2 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Nasopharyngeal Neoplasms 1 Mesothelioma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Immune-related Adverse Events 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

tocilizumab 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Columbia University

Phase 2 Active not recruiting

Other solid neoplasm

Immune-related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon ⚡